publication venue for
- Efficacy and safety of Sofosbuvir/Velpatasvir for the treatment of treatment-naive, non-cirrhotic patients with chronic hepatitis C genotype 3 infection: integrated analysis of three phase 3 clinical trials 2018
- Z-PROFILE: real-world utilization and effectiveness of Elbasvir/Grazoprevir in adult patients with chronic hepatitis C in Canada - final study results 2018
-
Mixed‐Genotype
HCV Direct Acting Antiviral Outcomes: ACANUHC Analysis. 31:775-779. 2024 - Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.. 27:143-155. 2020
- Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. 26:1127-1138. 2019
-
Real‐world impact of direct acting antiviral therapy on health‐related quality of life in
HIV /Hepatitis C co‐infected individuals. 25:1507-1514. 2018 - Estimating chronic hepatitis C prognosis using transient elastography‐based liver stiffness: A systematic review and meta‐analysis. 25:502-513. 2018
- Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.. 21:909-916. 2014
- Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. 18:153-160. 2011